Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prediabetic State 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary Neoplasms 1Neoplasms 1Lymphoma 1Iron Overload 1Hemoglobinopathies 1Diabetes Mellitus, Type 2 1Diabetes Mellitus, Type 1 1Diabetes Mellitus 1Cushing Syndrome 1Colorectal Neoplasms 1Bone Metastases 1

Interventions

relacorilant 5Pioglitazone 4Metformin 4Sitagliptin Phosphate 3Resistance Training 3Dipeptidyl-Peptidase IV Inhibitors 3saxagliptin 2Vildagliptin 2Sulfonylurea Compounds 2Rosiglitazone 2Nutritional Status 2Blood Specimen Collection 2voglibose 1somapacitan 1semaglutide 1repaglinide 1pembrolizumab 1miglitol 1metahexamide 1meglitinide 1mazdutide 1glymidine 1glisoxepide 1gliquidone 1glimepiride 1glibornuride 1empagliflozin 1dapagliflozin 1alogliptin 1Urine Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diabetes Mellitus, Type 2 × Continuous Glucose Monitoring × Clear all
NCT04942756 2021-07-22

GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using FreeStyle Libre 2 (FSL2) for Preventing Hyperglycemia/Hypoglycemia Crisis in Advanced Oncological Patients.

Antea Foundation

Phase NA Unknown
118 enrolled

Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡